Another main focus is on epilepsy. Almost 65 million people suffer from epilepsy, making it one of the most common neurological diseases worldwide. About one third of all epilepsy patients cannot be adequately treated with currently available anti-epileptic drugs.
One of the major challenges in epilepsy research is the identification of novel therapeutic targets. Moreover, there is an urgent need for reliable biomarkers that can predict whether epilepsy will develop, e.g. after brain trauma or other severe brain insult. Biomarkers could substantially improve the management of people with epilepsy and could lead to prevention in the right person at the right time.
In our studies we use neurophysiological (EEG, field potentials in vivo and intracellular recordings in (cultured) brain slices), anatomical (tracing, immuno- and histochemistry), molecular (in situ hybridization, quantitative-PCR, western blot, microarrays, next generation sequencing) and imaging (magnetic resonance imaging) techniques to get insight in the processes that ultimately lead to epilepsy. Using in vitro and in vivo preclinical models and resected brain tissue from patients, we seek to unravel the mechanisms of drug-resistance and development of epilepsy (=epileptogenesis), to find biomarkers and to apply a treatment that could prevent epilepsy. We presently focus on treatments aimed at the blood-brain barrier, neuroinflammation and the cannabinoid system.